|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Common genetic variants reported to be associated with BNP levels were not associated with a relevant risk of heart failure in our population-based cohort.
|
23315043 |
2013 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The comparison of prognosis⁻predictivity of a single measurement of plasma NT-pro BNP in different follow-up periods in acute HF patients has been less studied.
|
30871208 |
2019 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
TC could improve 6MWD, Qol and LVEF in patients with HF and may reduce BNP and HR.
|
29375390 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
[B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure].
|
19650993 |
2009 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Brain natriuretic peptide (BNP) gene expression accompanies cardiac hypertrophy and heart failure.
|
11230322 |
2001 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity.
|
11279304 |
2000 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
For example, GWAS of NT-proBNP levels not only identified variants in the NNPA-NPPB locus but also substantiated data suggesting that natriuretic peptides in itself are associated with a lower risk of hypertension and HF.
|
29912321 |
2018 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure.
|
24535859 |
2014 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
[B-type natriuretic peptide (BNP) levels and the effects of carvedilol on BNP levels in juvenile rats with right heart failure].
|
19650993 |
2009 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Nesiritide: past, present, and future.
|
16333235 |
2005 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
The prognostic value of big endothelin-1 in more than 2,300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT).
|
16762801 |
2006 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Clinical and hemodynamic effects of nesiritide (B-type natriuretic peptide) in patients with decompensated heart failure receiving beta blockers.
|
15860969 |
2005 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
CTD_human |
Carvedilol modulates the expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor in a rat model of volume-overload heart failure.
|
15732037 |
2005 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Resveratrol, an activator of SIRT1, upregulates AMPK and improves cardiac function in heart failure.
|
24535859 |
2014 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
The effects of atorvastatin (10 mg) on systemic inflammation in heart failure.
|
16360360 |
2005 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
RGD |
Increased plasma levels and blunted effects of brain natriuretic peptide in rats with congestive heart failure.
|
1831369 |
1991 |
|
Heart failure
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Use of natriuretic peptides for detecting cardiac dysfunction in long-term disease-free breast cancer survivors.
|
16101196 |
2005 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
LHGDN |
[BNP tests in the emergency department to diagnose congestive heart failure].
|
17086116 |
2006 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
By multiple linear regression analysis adjusted for age and sex, heart failure (HF) and BNP strongly associated with sST2 concentration.
|
29428199 |
2018 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We found that thrombin-induced COX-2 expression, PGE2 release and cardiomyocyte hypertrophy markers (increase in ANF/BNP, α-actin expression and cell surface area) was attenuated by pretreatment with CORM-2 which was partially reversed by hemoglobin (Hb) or ZnPP (an inhibitor of HO-1 activity), suggesting that HO-1/CO system may be of clinical importance to ameliorate heart failure through inhibition of inflammatory responses.
|
26385185 |
2015 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The measurements of plasma natriuretic peptides (NT-proBNP, proBNP and BNP) are used to diagnose heart failure but these are expensive to produce.
|
24101238 |
2014 |
|
Heart failure
|
0.600 |
GeneticVariation
|
disease |
LHGDN |
Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state.
|
16829184 |
2007 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
We investigated serum levels of UCN1, ADM, and pro BNP in 86 consecutive patients with systolic HF [ejection fraction (EF) ≤45%] and 85 healthy controls.
|
25868038 |
2017 |
|
Heart failure
|
0.600 |
Biomarker
|
disease |
BEFREE |
The developed LFIA for BNP could rapidly rule out HF with the naked eye, offering tremendous potential for POC test and personalized medicine.
|
28670119 |
2017 |
|
Heart failure
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Echocardiography and the expression of BNP showed that rivaroxaban attenuated heart failure.
|
30867376 |
2019 |